PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

1421PDIMPACT OF PDL1 EXPRESSION ON CLINICAL OUTCOMES IN SUBTYPES OF SARCOMA

(2017) S. Raj et al.   ANNALS OF ONCOLOGY

Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia

(2016) Ngai Cheung et al.   CANCER CELL

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

(2016) R. M. Chabanon et al.   CLINICAL CANCER RESEARCH

Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma

(2016) Priya Chudasama et al.   CLINICAL CANCER RESEARCH

Monitoring immune responses in the tumor microenvironment

(2016) Jennifer A Wargo et al.   CURRENT OPINION IN IMMUNOLOGY

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

(2016) Marlon C. Rebelatto et al.   Diagnostic Pathology

Genomic alterations of theJAK2andPDLloci occur in a broad spectrum of lymphoid malignancies

(2016) Katrien Van Roosbroeck et al.   GENES CHROMOSOMES & CANCER

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival

(2016) Jan Budczies et al.   GENES CHROMOSOMES & CANCER

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

(2016) Andreas H Scheel et al.   MODERN PATHOLOGY

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

(2016) Justin M. Balko et al.   Science Translational Medicine

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

(2016) Yusuke Inoue et al.   Oncotarget

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Immunotherapeutic Approaches to Sarcoma

(2015) Melissa Burgess et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

(2015) Sandra P. D’Angelo et al.   HUMAN PATHOLOGY

Contemporary diagnostics: Sarcoma pathology update

(2015) John S.J. Brooks et al.   JOURNAL OF SURGICAL ONCOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Antagonists of PD-1 and PD-L1 in Cancer Treatment

(2015) Evan J. Lipson et al.   SEMINARS IN ONCOLOGY

Immunotherapy in Sarcoma: Future Horizons

(2015) Melissa Burgess et al.   Current Oncology Reports

Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets

(2015) Sujana Movva et al.   Oncotarget

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

(2015) Michael T. Barrett et al.   Oncotarget

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies

(2014) Mark Linch et al.   Nature Reviews Clinical Oncology

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis

(2014) Ilana Kupershmit et al.   NUCLEIC ACIDS RESEARCH

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas

(2013) Jung Ryul Kim et al.   PLoS One

Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas

(2013) Marcus Renner et al.   GENOME BIOLOGY

Cancer classification using the Immunoscore: a worldwide task force

(2012) Jérôme Galon et al.   Journal of Translational Medicine

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates

(2011) W. H. Fridman et al.   CANCER RESEARCH

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

(2011) Françoise Ducimetière et al.   PLoS One

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma

(2008) Vasilios Karavasilis et al.   CANCER

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY